Hello Xistre
Thank you for looking at the issues I raised … it is longpast due that we all looked in a global sense at the core issues
Approx. 10 years ago we were led to believethat there was a great need in the patch market for a solution to the needs ofhole-in-heart kids ... Turns out that the initial product offering was notsufficiently tailored to the surgeons’ needs. Years of non-sales followed. Presentday we have a product for this purpose which is correctly sized and thicknesscontrolled, with a history of successful use BUT sales are NOT increasing.Something is fundamentally wrong at the point of purchase decision.· Vascucell is the same … seems to be a greatproduct BUT except for a core group of on-side surgeons market share is NOTgrowing
· Going back approx. 3 years or so we were givenlots of background stories about how the efficiencies in our factory were dramaticallyimproved and, for example, by making the hole-in-the-heart patch smaller thecosts of manufacture were very very good (= competitive). News andbackgrounding from our factory has been sadly lacking for a couple of yearsnow.
· About 4 years ago we had a USA sales forcewhich I thought was an embarrassment … that crew seemed to be all suddenly “notthere” … we had distributors appointed all over the world but sales did notseem to arrive … Typically in high-tech industrial products it is highlyskilled professional sales staff that break through with a new product … weseem to be doing this with a small sales staff for our new 3D product, but whatabout the rest? Europe doesn’t seem to be served at all and distributors arejust the usual ineffective order-takers. India is an embarrassment in itself …there at day 1 and gone at day 2. What is happening in China.
· What has been happening with the outputexpected from the highly expensive professional hired last May to processapprovals? … Australia TGA approval was expected in July. What happened?
· Now we have very recently hired a new staffmember at great expense . Chief Medical Officer … of what? …
· It is obvious that Admedus is not serious aboutgrowing Adapt … they are padding out the organization with people whose outputis to facilitate TAVR … blue sky.
· I heard that our great “breakthrough” into ahospital group purchasing setup was such that it was Admedus and 1 othersupplier, and yet nothing happened. Why? Obviously the system didn’t care aboutour higher-priced offering. What are our skilled field staff doing about this?
The blue sky of TAVR is sucking us dry just as vaccines usedto do … at the very least we-who-are-paying need much much more news about allaspects.
Sales effort is not up to scratch.
Certainly distributors are proving to be just order-takers... and what happened to India? ... and MENA? ...
My personal background is in professional sales of high tech industrial products ... I find Admedus's inadequate efforts so very frustrating.
D
- Forums
- ASX - By Stock
- Ann: Appendix 4C - quarterly
Hello XistreThank you for looking at the issues I raised … it...
-
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVR (ASX) to my watchlist
|
|||||
Last
$15.15 |
Change
0.000(0.00%) |
Mkt cap ! $291.2M |
Open | High | Low | Value | Volume |
$15.00 | $15.15 | $14.60 | $347.8K | 23.20K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 760 | $15.00 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$15.15 | 388 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 760 | 15.000 |
3 | 2651 | 14.950 |
1 | 100 | 14.800 |
1 | 203 | 14.760 |
1 | 364 | 14.600 |
Price($) | Vol. | No. |
---|---|---|
15.150 | 388 | 1 |
15.300 | 1000 | 1 |
15.350 | 88 | 1 |
15.700 | 277 | 1 |
15.880 | 250 | 1 |
Last trade - 15.58pm 30/07/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |
The Watchlist
MTL
MANTLE MINERALS LIMITED
Nick Poll, Executive Director
Nick Poll
Executive Director
SPONSORED BY The Market Online